Search for Clinical Trial Results
Amyloidosis - 257 Studies Found
Status | Study |
Completed |
Study Name: Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Condition: Multiple Myeloma and Plasma Cell Neoplasm Date: 2007-05-23 Interventions:
|
Terminated |
Study Name: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation Condition:
Date: 2003-01-24 Interventions:
|
Active, not recruiting |
Study Name: A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) Condition:
Date: 2013-11-18 Interventions:
|
Active, not recruiting |
Study Name: Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis Condition: Multiple Myeloma Date: 2004-01-09 Interventions:
|
Terminated |
Study Name: 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis Condition:
Date: 2004-01-09 Interventions:
|
Completed |
Study Name: Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Condition: Multiple Myeloma and Plasma Cell Neoplasm Date: 2001-01-06 Interventions:
|
Withdrawn |
Study Name: Mixed Chimeric Transplantation for Primary Amyloidosis Condition: Date: 2024-09-28 |
Active, not recruiting |
Study Name: Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Condition: Amyloidosis Date: 2009-11-02 Interventions:
|
Completed |
Study Name: Autologous Stem Cell Rescue for Primary Amyloidosis Condition:
Date: 2005-09-13 Interventions: Procedure: high dose chemo then auto hematopoietic cell transplant |
Completed |
Study Name: Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis Condition: Amyloidosis Date: 2005-09-12 Interventions: Drug: CC-5013 40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle |